News and events

ShARE Project report released

16 August 2016

The report written by Joyce Tait on ‘Environmental regulation of synthetic biology: anticipating future regulatory oversights’ is published.

New RSE Young Academy of Scotland member

12 July 2016

Niki Vermeulen is appointed member of the RSE Young Academy of Scotland (YAS).

Gene Drives on the Horizon

23 June 2016

Joyce Tait and Ann Kingiri contributed to a recent high profile report on gene drive research from the U.S. National Academy of Sciences.

O’Neill Commission Report on AMR released

19 May 2016

This review on AMR, proposed in an Innogen report in 2015, assesses solutions to the spread of drug resistance.

New body AsSIST-UK set up with the explicit goal of engaging with science and science policy

6 April 2016

The formal launch on the 6th April 2016 of the ‘Association for Studies in Innovation Science and Technology-UK’ was co-chaired by Andrew Webster and Robin Williams.

Political Studies Association (PSA) 66th Annual International Conference

21 March 2016

Theo Papaioannou, Andrew Watkins, Dinar Kale and Julius Mugwagwa participate in the PSA Annual International Conference 21 – 23 March 2016.

Niki Vermeulen working on ‘Virtual Edinburgh’ initiative with Bill Jenkins at STIS

1 March 2016

‘Curious Edinburgh’ is a project about the history of science, technology and medicine in Edinburgh.

Innogen Success in REF 2014

14 January 2016

The Innogen Institute, based at the University of Edinburgh and the Open University, achieved excellent results in the latest UK research evaluation, called the Research Excellence Framework (REF).

IBioIC’s 2nd Annual Conference: ‘Realising the Opportunity’

7 January 2016

Joyce Tait discussed ‘The Challenges & Barriers to Industrial Biotechnology’ on 29 January 2016 at the IBioIC’s Conference.

James Mittra’s new book ‘The New Health Bioeconomy - R&D Policy and Innovation for the Twenty-First Century’ now available

26 November 2015

This book provides original insights into how “new biology” and “translational” policies to drive a health bioeconomy are reshaping innovation ecosystems, and disrupting R&D practices, institutional and professional boundaries, and notions of “value” in healthcare.